Programmed cell death-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) pathway-targeted immunotherapy has become the standard option of care in the management of lung cancer. The expression of the PD-L1 protein in lung cancer is expected to be a prognostic factor or to predict the response to PD-1-blocking antibodies. However, the association between PD-L1 positivity and the clinicopathological features and patient outcomes in lung squamous cell carcinoma (SCC) remains unclear because the definitive cut-off value for the expression of PD-L1 protein remains to be established.The expression of PD-L1 protein in 205 surgically resected primary lung SCC patients was evaluated by immunohistochemistry with the antibody clone SP142. We generated a histogram to show the proportion of PD-L1-positive carcinoma cells, and set the cut-off values as 1

作者：Kazuki, Takada；Tatsuro, Okamoto；Gouji, Toyokawa；Yuka, Kozuma；Taichi, Matsubara；Naoki, Haratake；Takaki, Akamine；Shinkichi, Takamori；Masakazu, Katsura；Fumihiro, Shoji；Yoshinao, Oda；Yoshihiko, Maehara

来源：Lung cancer (Amsterdam, Netherlands) 2017 年 104卷